CatherineCCoombsMD

PubMed

• Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
  Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach
  Haematologica. 2025-01-01
• Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
  Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, Nicole Lamanna, Beenish S Manzoor
  American Journal of Hematology. 2024-12-19
• Interindividual variability in CYP3A-mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia.
  Jonghwa Lee, Jessica L Beers, Isabel Cheng, Vivian Truong, Zachary Brown
  Clinical and Translational Science. 2024-12-01

Abstracts/Posters

• Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all